dexycu

EyePoint Pharmaceuticals, Inc., a biopharmaceutical company headquartered in Watertown, Massachusetts, has reached a settlement with the United States government, agreeing to pay $4,657,463.18 to resolve allegations that it violated the False Claims Act. The settlement addresses claims that the company engaged in an illegal kickback scheme designed to induce ambulatory service centers (ASCs) to purchase and dispense DEXYCU, an injectable steroid used to treat inflammation following cataract surgery. According to the Department of Justice, these activities occurred between January 1, 2019, and March 1, 2023, creating a period of several years where medical decision-making was allegedly tainted by financial incentives.

The resolution of this matter highlights the federal government’s ongoing commitment to policing the relationship between pharmaceutical manufacturers and healthcare providers. In addition to the federal payment, EyePoint has agreed to pay an additional $21,518.68 to several participating states whose Medicaid programs were affected by the alleged misconduct. As part of the settlement, EyePoint has also entered into a comprehensive five-year Corporate Integrity Agreement with the Department of Health and Human Services Office of Inspector General (HHS-OIG), which will mandate strict oversight of the company’s compliance and marketing practices moving forward.

The Mechanics of the Alleged Kickback Scheme

The core of the government’s allegations involves two primary methods through which EyePoint allegedly induced ASCs to utilize DEXYCU over competing treatments. Following the commercial launch of the drug in early 2019, EyePoint faced the challenge of penetrating a competitive market for post-operative ocular care. To gain market share, the government alleges that the company implemented what it termed an "Assurance Program."

Under the parameters of this Assurance Program, EyePoint allegedly offered to reimburse or compensate ASCs if their claims for DEXYCU were denied by health insurers or if the reimbursement rate fell below the purchase cost the ASC had paid to EyePoint. In the healthcare industry, such "make-whole" arrangements are often viewed as illegal inducements because they eliminate the financial risk for the provider, thereby encouraging them to select a specific drug based on financial safety rather than clinical superiority or cost-effectiveness for the taxpayer.

Furthermore, the United States alleged that EyePoint provided excessive quantities of free samples of DEXYCU to ASCs. While the distribution of drug samples is a common industry practice, the government contended that the volume and frequency of these samples exceeded legitimate clinical needs and functioned as a form of "in-kind" kickback. By providing free units that could be dispensed to patients, the company effectively lowered the net cost of the drug for the centers, creating an artificial financial incentive to favor EyePoint’s product in their surgical protocols.

Background on DEXYCU and the Ophthalmic Market

DEXYCU (dexamethasone intraocular suspension) was approved by the U.S. Food and Drug Administration (FDA) as a long-acting, single-dose injectable steroid. It was designed to replace the traditional regimen of steroid eye drops that patients must self-administer for several weeks following cataract surgery. Cataract surgery is one of the most frequently performed medical procedures in the United States, with millions of operations conducted annually, primarily on the elderly population covered by Medicare.

Because DEXYCU is administered by the physician during the surgery, it is typically billed under Medicare Part B or other medical insurance, rather than through a pharmacy benefit. This billing structure places the financial responsibility for purchasing the drug on the surgical facility, which then seeks reimbursement from insurers. The "Assurance Program" was specifically designed to address the "buy-and-bill" anxiety felt by ASCs, who feared that if Medicare or private insurers did not fully cover the high cost of the injectable, the facility would be left with a significant financial loss. By removing this risk, EyePoint allegedly bypassed the natural market forces that keep drug prices and usage in check.

The Role of the Whistleblower and Qui Tam Litigation

The investigation into EyePoint’s marketing practices was initiated under the qui tam, or whistleblower, provisions of the False Claims Act. These provisions allow private parties with knowledge of fraud against the government to file a lawsuit on behalf of the United States. In this case, the action was brought by AFCE LLC.

Whistleblowers, known legally as "relators," play a critical role in the enforcement of healthcare laws, as they often have access to internal documents and communications that government investigators might not otherwise see. As a reward for bringing the misconduct to light and assisting in the recovery of federal funds, AFCE LLC will receive a portion of the settlement proceeds. Specifically, the relator is slated to receive $791,768.74 from the federal recovery.

The successful resolution of this case, captioned U.S. ex rel. AFCE LLC, et al., v. EyePoint Pharmaceuticals, Inc., demonstrates the power of the False Claims Act as a tool for transparency. Without the intervention of the relator, the Assurance Program might have continued to operate unnoticed, potentially costing federal healthcare programs millions more in unnecessary expenditures.

Official Statements and Government Response

Federal officials were clear in their condemnation of the alleged practices, emphasizing that kickbacks have no place in the American healthcare system. Assistant Attorney General Brett A. Shumate of the Justice Department’s Civil Division noted that illegal incentives drive up costs for everyone. "Kickbacks by pharmaceutical companies increase the cost of drugs used by patients and paid for by federal health care programs," Shumate stated. "The Civil Division will hold accountable anyone who pays unlawful kickbacks."

United States Attorney Leah B. [Foley/Wainwright – reference to District of Massachusetts] echoed these sentiments, highlighting the office’s long-standing focus on pharmaceutical integrity. "As we have for years, our Office will continue to hold pharmaceutical manufacturers accountable for paying illegal kickbacks. Through these efforts, we protect patients by removing providers’ financial incentives to prescribe or dispense products that may not be medically necessary."

Acting Deputy Inspector General for Investigations Scott J. Lampert of the HHS-OIG underscored the betrayal of trust inherent in such schemes. "Pharmaceutical companies that attempt to boost profits through unlawful kickbacks undermine the integrity of federal health care programs and betray the patients who rely on them," Lampert said. He added that the HHS-OIG would "aggressively pursue any entity that seeks to corrupt medical decision making."

The Five-Year Corporate Integrity Agreement

A significant component of the resolution is the Corporate Integrity Agreement (CIA) EyePoint entered into with the HHS-OIG. A CIA is a common requirement in healthcare fraud settlements involving large corporations. It serves as a probationary period during which the company must adhere to strict compliance standards to ensure that the misconduct does not recur.

Under the terms of the five-year agreement, EyePoint will be required to:

1. Establish a Compliance Committee: This body must include senior management and be overseen by a Board of Directors committee.
2. Implement Mandatory Training: Employees and contractors involved in sales and marketing must undergo regular training on the Anti-Kickback Statute and the False Claims Act.
3. Engage an Independent Review Organization (IRO): An outside firm must be hired to conduct annual reviews of the company’s systems, policies, processes, and transactions.
4. Report to the HHS-OIG: The company must provide regular reports on its compliance efforts and disclose any further violations of healthcare laws.

Failure to comply with the CIA can result in significant financial penalties or, in extreme cases, exclusion from participating in federal healthcare programs like Medicare and Medicaid—a move that would be catastrophic for any pharmaceutical manufacturer.

Broader Impact on the Pharmaceutical Industry

The EyePoint settlement is part of a broader trend of increased enforcement targeting "patient assistance" and "provider assurance" programs. While these programs are often marketed as ways to increase patient access to expensive medications, the DOJ has increasingly viewed them as sophisticated covers for kickbacks. When a manufacturer offsets the financial risk for a provider, it effectively "pays" that provider to choose their product over a competitor’s, violating the Anti-Kickback Statute.

The investigation was a collaborative effort involving several high-level agencies, including the Justice Department’s Civil Division, the Commercial Litigation Branch, the Fraud Section, the U.S. Attorney’s Office for the District of Massachusetts, the Federal Bureau of Investigation (FBI), and the HHS-OIG. This multi-agency approach reflects the government’s "war on fraud," which was further bolstered this year by the launch of the Task Force to Eliminate Fraud and the National Fraud Enforcement Division.

These new administrative bodies are designed to enhance the government’s ability to detect and prosecute fraud, waste, and abuse in federal programs. By pooling resources and expertise, the administration aims to recover billions of dollars for American taxpayers and ensure that medical decisions are based on patient health rather than corporate profit margins.

Conclusion and Future Outlook

The settlement with EyePoint Pharmaceuticals serves as a stern warning to the pharmaceutical industry that the government is closely monitoring how drugs are marketed and sold to surgical centers and hospitals. As medical technology advances and new, expensive injectables enter the market, the temptation to offer financial "safety nets" to providers remains high. However, the $4.6 million penalty and the subsequent five years of federal oversight demonstrate that the cost of such shortcuts far outweighs any temporary gain in market share.

For the public, the resolution of this case is a victory for the integrity of the healthcare system. It reinforces the principle that the relationship between a doctor and a patient should be sacred, free from the corrupting influence of undisclosed financial arrangements. As the Task Force to Eliminate Fraud continues its work, industry observers expect to see a continued surge in False Claims Act litigation, particularly in the ophthalmic and surgical sectors where "buy-and-bill" drugs are most prevalent.

Taxpayers and patients alike are encouraged to remain vigilant. The Department of Health and Human Services continues to maintain its hotline (800-HHS-TIPS) for reporting potential fraud, waste, or mismanagement. With the government’s renewed emphasis on accountability, the EyePoint case likely represents just one chapter in a much larger effort to cleanse the federal healthcare landscape of unscrupulous financial practices.